Stryker Rejuvenate and ABG II Hip Implant
The Stryker Rejuvenate and ABG II MDL was centralized in June 2013 after these modular-neck hip implant systems were voluntarily recalled over concerns about fretting and corrosion at the modular junction, which could release metal debris and cause tissue damage requiring revision surgery. The litigation moved relatively quickly toward a large settlement program that resolved the substantial majority of claims, and the docket has carried a low single-digit or low-double-digit pending count for years since.
With only six actions currently pending, this docket sits firmly in a terminal, post-settlement phase. The structural question that matters most for any case still open here is not a general-causation question — the corrosion-and-fretting failure mechanism and its injury consequences were extensively characterized during the litigation's active phase — but rather why a specific claim was not resolved through the settlement program that closed out most of the docket. That could reflect a later diagnosis, a claim filed after the settlement program's eligibility window, or a dispute over whether a particular claim meets the program's injury or product criteria.
This is a useful example of a broader pattern across modular hip-implant litigation: once a well-characterized mechanical failure mode is established and a settlement program is built around it, the docket's remaining resolution risk becomes almost entirely about eligibility and individual claim facts rather than about the underlying science, which has already been substantially settled through the litigation record even without a trial verdict resolving it definitively.
Criterica Intelligence tracks this terminal-phase pattern — where a docket's core causation questions have effectively been resolved through settlement architecture and what remains is claim-specific eligibility and timing — as one of several distinct structural profiles the platform surfaces across the active MDL landscape.
These modular-neck hip implant systems were voluntarily recalled after reports of fretting and corrosion at the modular junction, which could release metal debris and require revision surgery — the basis for the consolidated product-liability claims.
A large settlement program resolved most claims in this docket years ago; a docket at this stage typically retains only claims that fell outside that program's eligibility parameters or were diagnosed later.
Not really — the corrosion-and-fretting failure mechanism was extensively developed during the litigation's active phase and effectively resolved through the settlement architecture, even without a trial verdict; remaining disputes are largely about individual claim eligibility.
It proceeds on an individual basis toward trial, relying on the causation and defect record already developed during the docket's active litigation years rather than reopening the underlying scientific questions.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.